The novel ataxia telangiectasia–mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.
The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors, according to phase 1 results of the AcSé-ESMART trial.The data, presented at American Association for Cancer Research Annual Meeting, also showed ceralasertib (AZD6738, AstraZeneca) plus olaparib (Lynparza, AstraZeneca) — a